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Abstract
Background: In 2008 Fiji implemented a nationwide Human Papillomavirus (HPV) vaccine campaign targeting all
girls aged 9–12 years through the existing school-based immunisation program. Parents of vaccine-eligible girls
were asked to provide written consent for vaccination. The purpose of this study was to describe parents’
knowledge, experiences and satisfaction with the campaign, the extent to which information needs for vaccine
decision-making were met, and what factors were associated with vaccine consent.
Methods: Following vaccine introduction, a cross-sectional telephone survey was conducted with parents of
vaccine-eligible girls from randomly selected schools, stratified by educational district. Factors related to vaccine
consent were explored using Generalised Estimating Equations.
Results: There were 560 vaccine-eligible girls attending the participating 19 schools at the time of the campaign.
Among these, 313 parents could be contacted, with 293 agreeing to participate (93.6 %). Almost 80 % of
participants reported having consented to HPV vaccination (230/293, 78.5 %). Reported knowledge of cervical
cancer and HPV prior to the campaign was very low. Most respondents reported that they were satisfied with their
access to information to make an informed decision about HPV vaccination (196/293, 66.9 %). and this was very
strongly associated with provision of consent. Despite their young age, the vaccine-eligible girls were often
involved in the discussion and decision-making. Most consenting parents were satisfied with the campaign and
their decision to vaccinate, with almost 90 % indicating they would consent to future HPV vaccination. However,
negative media reports about the vaccine campaign created confusion and concern. Local health staff were cited
as a trusted source of information to guide decision-making. Just over half of the participants who withheld
consent cited vaccine safety fears as the primary reason (23/44, 52.3 %).
(Continued on next page)
* Correspondence: sophie.lavincente@rch.org.au
1Centre for International Child Health, Murdoch Childrens Research Institute,
Royal Children’s Hospital, Flemington Road, Parkville, VIC 3052, Australia
2Department of Paediatrics, University of Melbourne, Royal Children’s
Hospital, Flemington Road, Parkville, VIC, Australia
Full list of author information is available at the end of the article
© 2015 La Vincente et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
La Vincente et al. BMC Public Health  (2015) 15:1257 
DOI 10.1186/s12889-015-2579-3
(Continued from previous page)
Conclusion: This is the first reported experience of HPV introduction in a Pacific Island nation. In a challenging
environment with limited community knowledge of HPV and cervical cancer, media controversy and a short lead-
time for community education, Fiji has implemented an HPV vaccine campaign that was largely acceptable to the
community and achieved a high level of participation. Community sensitisation and education is critical and should
include a focus on the local health workforce and the vaccine target group.
Keywords: HPV vaccination, Fiji, Vaccine acceptance, Vaccine decision-making
Background
Cervical cancer is the third most common cancer in
women worldwide, and a leading cause of mortality
amongst women [1]. The greatest cervical cancer burden
is in low-resource settings, with 85 % of new cases
and almost 90 % of mortality occurring in low and
middle income countries [1] where access to cancer
screening and treatment is often very limited. The
Human Papillomavirus (HPV) causes almost all cases
of cervical cancer [2]. The development of a vaccine
that provides protection against the most common,
and most cancer-causing, types of HPV is a major step
towards reducing cervical cancer rates. Infection with
HPV is also recognised to cause a number of other
cancers [3], as well as genital warts, a condition
around which there is substantial stigma and negative
impact on quality of life [4, 5]. Thus there is potential
for a much broader health impact of HPV vaccine use
beyond reduction of cervical cancer.
The potential for vaccine introduction to reduce dis-
ease burden relies on community acceptance and uptake
of the vaccine. Effective community education and
awareness-raising is a key component of any new vac-
cine introduction [6]. Such activities may be particularly
important in the case of HPV vaccine for a number of
reasons. Studies across a range of settings have revealed
there is typically limited knowledge about HPV among
the general population [7–12]. Further, the virus is sexu-
ally transmissible. To ensure women are protected, the
vaccine is ideally delivered prior to sexual contact, thus
a key target population for vaccination is young ado-
lescents. As such there may be strong cultural and
social factors influencing community acceptance of
the vaccine [7, 13].
Early experience with HPV vaccine, and in particular
the implementation of a nation-wide campaign, was re-
stricted to high-income countries. Recognising the high
burden of cervical cancer and with increasing access to
the vaccine through the GAVI Alliance’s support of HPV
vaccine implementation [14], the last decade has seen a
substantial expansion of HPV vaccine introduction in
low and middle income countries (LMIC). These experi-
ences are generating a growing body of literature on the
acceptability of the vaccine in these varied settings, what
factors have been important for successful implementa-
tion, and what lessons have been learnt in each country.
Such experiences are critical to strengthen vaccine pro-
grams in those countries, and to inform introduction
elsewhere.
The burden of cervical cancer in the Pacific region is
very high, with rates in Melanesian islands among the
highest reported worldwide [1, 15–17]. A 2015 report
noted that senior Pacific country health officials ranked
public perception about the HPV vaccine and its safety
as one of the leading barriers to effective introduction of
the vaccine [17], To date there has been no information
on community acceptability of the vaccine, or of the
experience of vaccine introduction in this region.
The Republic of the Fiji Islands is an archipelago of
several hundred islands in the South Pacific. With a
population of just under 850,000 it is one of the most
populous of the South Pacific Island nations. While Fiji
made steady progress across many development goals
during the 1990s, progress has more recently slowed
and it is unlikely that poverty targets and several key
health goals will be met [18]. Fiji has a very high burden
of cervical cancer, with an estimated age-standardised
incidence of 27.6 cases per 100,000 women (2003–2009)
[19]. Data indicate the available HPV vaccines could re-
duce cervical cancer in Fiji by up to 80 % [20]. Cytology-
based cervical cancer screening was included in Fiji’s
overall Cancer Control Programme in 1995; however as
in many LMICs, coverage of Papanicolaou (Pap) smear
testing remains very low, reaching only 10 % of eligible
women [21]. Resource constraints limit the scope of the
screening program (for example, a lack of human re-
source caps the number of tests that can be performed
each year, and there is very limited program advocacy
and mobilisation), and this is likely an important barrier
to broader uptake [21].
Given the high burden of cervical cancer in Fiji and
the existence of a well-functioning school-based immun-
isation programme, the Ministry of Health (MoH) im-
plemented a one-off national HPV vaccine campaign in
2008 following the donation of 110,000 doses of quadri-
valent HPV vaccine. This was one of the first experi-
ences of HPV vaccine introduction in a low- or middle-
income Pacific nation.
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The HPV vaccine campaign in Fiji commenced in late-
2008, with administration of the 3-dose HPV vaccine
primarily through the existing school-based immunisa-
tion program. There was enough vaccine available to
vaccinate four birth cohorts (30,338 girls aged 9–12
years) with a 3-dose schedule. Due to the limited shelf-
life of the donated vaccine and the approaching school
holidays, less than two months were available for com-
munity sensitisation prior to vaccine introduction. To
capture the target age group of 9 to 12 year olds, all girls
in classes 4 to 7 were eligible for vaccination. The vac-
cine was also offered free-of-charge at health centres to
age-eligible girls who had missed school-based adminis-
tration. A concerted awareness-raising strategy was
undertaken to educate the population about HPV and
promote vaccine uptake by the target group, both in the
short period of time prior to vaccine introduction and
during campaign roll-out. This communication was di-
rected at parents of school-aged children, with written
parental consent being required for vaccination. An in-
formation pamphlet for parents outlined key issues
about cervical cancer, HPV and reasons for vaccination,
side-effects and safety of the vaccine, as well as details of
the vaccine campaign including eligibility and timing.
The Ministry of Health also worked closely with the
Ministry of Education to engage schools and teachers in
the communication strategy. The Ministry of Education
was involved in the planning and timing of the cam-
paign. Nurses involved in implementing the program
met with teachers to explain the program. Teachers
organised for the information pamphlet and consent
forms to be taken home by eligible students. An
awareness-raising campaign was also run through the
media, including advertisements and information pre-
sented on the radio, television and in newspapers. A
number of negative reports appeared in the media ques-
tioning the safety of the vaccine and the motivation of
the government and vaccine manufacturer. A vigorous
media debate ensued, which created significant hype and
controversy around the vaccine campaign. The MoH
and other supporting agencies responded swiftly to
counter the concerns generated by the negative press.
Understanding the information needs and attitudes of
parents in relation to HPV vaccine delivery is critical to
ensure vaccination programs achieve a high level of up-
take [22]. The aim of this study was to describe parents’
knowledge, experiences and satisfaction with the cam-
paign in Fiji, the extent to which information needs for
vaccine decision-making were met, and to identify fac-
tors that were associated with vaccine consent.
Methods
A list of primary schools in each of the nine educational
districts was provided by the Ministry of Education.
From this list of 724, 25 schools were randomly selected,
stratified by educational district. We aimed to inter-
view all parents of vaccine-eligible girls attending the
selected schools. The research team first contacted
each school to request their assistance. Schools pro-
vided contact details for the parents of all girls in eli-
gible classes at the time of the vaccination program
and notified parents of these students about the up-
coming survey.
A telephone-based questionnaire was developed and
initially pilot tested with parents from two schools. A
combination of open and closed questions focused on
knowledge and attitudes about HPV, cervical cancer and
HPV vaccine prior to and after the vaccine campaign;
HPV vaccine decision-making, including information
sources and satisfaction with available information; par-
ticipation in the campaign; concerns about the vaccine
or the campaign and, among non-consenting parents,
reasons for withholding consent. Demographic informa-
tion was also collected. Interviews were conducted by
two Fijian research assistants trained in the administra-
tion of the questionnaire, including the use of standard
prompts. Using the contact lists provided by the schools,
parents were contacted by telephone and invited to par-
ticipate in the survey. Three attempts of contact at dif-
ferent times of day and on different days were made for
each contact number provided by the school. Verbal in-
formed consent was obtained from participants prior to
interview. Responses were coded and entered by re-
search team members in Fiji.
Data were transferred to Stata13 for analysis. Test of
proportions was used to assess the change in self-
reported awareness of HPV and cervical cancer before
and after the vaccine campaign. We assessed the
relationship between vaccine acceptance (self-reported
provision of consent) and potential explanatory variables
using logistic regression, employing the method of mar-
ginal models estimated using Generalised Estimating
Equations (GEE) with information sandwich estimates of
variance. GEE was used given the potential for clustering
by school. These analyses were performed in Stata using
the xtgee command. Simple (univariate) GEE was ini-
tially performed to examine the relationship between
vaccine acceptance and each explanatory variable of
interest, followed by multivariate GEE including ex-
planatory variables found to be significant associated
with consent in univariate analysis or considered to be
potential confounders.
The survey was undertaken from November 2009 to
March 2010, following scheduled delivery of the third
dose of the HPV vaccine. The study was approved by the
Fiji National Research Ethics Review Committee, and
the Human Research Ethics committee of the University
of Melbourne, Australia.
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Results
Survey participation and sample characteristics
Of the 25 schools randomly selected for participation,
three schools were excluded as they were subsequently
identified to be schools for boys only. A further three
schools from a remote northern region were excluded
due to communication difficulties following a cyclone.
All of the 19 remaining randomly selected schools
agreed to assist.
Class lists provided by the schools indicated that a
total of 560 vaccine-eligible girls attended the participat-
ing 19 schools at the time of the campaign. Among these
560, 247 parents could not be reached by the research
team due to incorrect or missing phone number. Among
the 313 parents who were contacted and invited to par-
ticipate, a total of 293 agreed (93.6 %).
Most participants identified as the mother of the
vaccine-eligible girl (235/293, 80.2 %) and had a median
age of 40 years (IQR 36, 43) (Table 1). The distribution
of participants across the three main geographic regions
of Fiji was largely consistent with the broader population
distribution [23]. The large majority of respondents
reported that their daughter received the routine immu-
nisations provided through the school-based program
(270/293, 92.2 %).
Awareness and knowledge of cervical cancer and HPV
Participants reported very little knowledge of cervical
cancer or HPV prior to the campaign (Table 1). Only 30
participants (10.2 %) reported having heard of HPV
before the vaccine campaign. Sixty-two respondents
(21.2 %) reported having heard of cervical cancer before
the campaign, and the majority of these knew someone
who had the disease (47/62, 75.8 %). Most had heard
of pap smear (219, 74.7 %) and almost all of those re-
spondents considered it somewhat (6/219) or very
(211/219) important for women in Fiji to have pap
smear screening.
The information campaign significantly increased self-
reported awareness of cervical cancer (p < 0.001). Over
80 % (239/293, 81.6 %) of respondents reported know-
ledge of cervical cancer at the time of survey, and most
(177/293, 60.4 %) reported having only become aware of
cervical cancer through the vaccine campaign. Many
participants believed cervical cancer to be common
among women in Fiji (193/293, 65.9 %). Awareness of
HPV also significantly increased, with just under a third
(87/293) of participants reporting knowledge of HPV at
the time of survey (p < 0.001).
Information and decision-making
Over half of the respondents reported feeling that
they had sufficient information to make a decision to
accept or decline vaccination for their daughter
(Table 1) (196/293, 66.9 %). The majority reported
that their primary source of information about cer-
vical cancer, HPV and the vaccination campaign was
the information pamphlet provided to parents of eli-
gible girls (219, 75 %). While most respondents re-
ported that the source of health information they
trust most is their local nurse or family physician
(259/293, 88.4 %), few reported having obtained fur-
ther information or advice about the vaccine cam-
paign from a health provider or other community
member (48, 16.4 %). By contrast, most respondents
reported having discussed the decision with a family
member (182, 62.1 %), and the majority also reported
having involved their daughter in the decision about
vaccination (213, 72.7 %).
Additional information needs focused on the long-
term safety, potential side-effects, and the relative advan-
tages and disadvantages of vaccination. Several respon-
dents also wanted more information about why girls
were being vaccinated at such a young age, and how sex-
ual intercourse could lead to cancer. Negative media re-
ports were described as having created confusion, with
some participants noting that they would have liked
more information to clarify the claims made by those
reports.
Some schools had been vocally opposed to the cam-
paign and had resisted the nurses’ attendance on the
scheduled vaccination days. Most respondents perceived
their daughter’s school had been supportive of the cam-
paign (180/293, 61.4 %). Seven respondents (2.4 %) re-
ported the school had been openly opposed to the HPV
vaccine program, representing four different schools;
however, all but one of these families reported consent-
ing to vaccination notwithstanding the school’s position.
Vaccine acceptance
Almost 80 % of participants reported that they had
consented to their daughter receiving the HPV vac-
cine (230/293, 78.5 %) (Table 1, Fig. 1). Over half re-
ported that their daughter had received all three
doses (170/293, 58.0 %), which is consistent with
broader population figures of 55 % coverage for the
third dose [24]. Among the 39 consented children
who did not receive all three doses, absence from
school during vaccination was the most common rea-
son given (16/39, 41.0 %). The large majority of con-
senting parents were happy with their decision, with
few parents reporting any subsequent concern about their
decision to consent to vaccination (14/230, 6.1 %).
In univariate GEE analysis, respondents who reported
feeling that they had sufficient information to make an
informed decision about vaccination were significantly
more likely to consent to vaccination (OR 180.38, 95 %
CI 18.26, 1781.92, p < 0.001) (Table 2). Almost all who
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reported having access to sufficient information gave
consent for vaccination (192/193, 99.5 %). Among non-
consenting parents, almost all (43/44) either said they
didn’t have (n = 17), or weren’t sure if they had (n = 26),
sufficient information to make a decision. Believing that
women in Fiji are at risk of HPV and that cervical cancer
is common in Fiji were also significantly associated with
Table 1 Participant characteristics (n = 293)
N (%)
Demographics
Age of respondent (years) (med,IQR) 40 (36,43)
Relationship of respondent to eligible girl
Mother 235 (80.2 %)
Father 39 (13.3 %)
Other guardian 14 (4.8 %)
Region
Central/Eastern Division 177 (60.4 %)
Western Division 90 (30.7 %)
Northern Division 26 (8.9 %)
Education of respondent
Primary school only 40 (13.7 %)
Secondary school or higher 233 (79.5 %)
Household weekly income, $FJ
<100 86 (29.4 %)
100-199 129 (44.0 %)
200+ 78 (26.6 %)
Vaccine uptake
Consent given for HPV vaccination
Yes 230 (78.5 %)
No 44 (15.0 %)
Don’t know 19 (6.5 %)
Eligible girl reported to have received all three doses
Yes 170 (73.9 %)
No 39 (17.0 %)
Don’t know 21 (9.1 %)
Eligible girl reported to receive other routine school
vaccines
Yes 270 (92.2 %)
No 1 (0.3 %)
Don’t know 19 (6.5 %)
Awareness and knowledge
Heard of HPV before campaign
Yes 30 (10.2 %)
No 242 (82.6 %)
Don’t know 17 (5.8 %)
Heard of cervical cancer before campaign
Yes 62 (21.2 %)
No 222 (75.8 %)
Don’t know 8 (2.7 %)
Consider cervical cancer common in Fiji
Yes 193 (65.9 %)
No 39 (13.3 %)
Don’t know 60 (20.5 %)
Table 1 Participant characteristics (n = 293) (Continued)
Consider women in Fiji at risk of HPV
Yes 190 (64.9 %)
No 73 (24.9 %)
Don’t know 26 (8.9 %)
Heard of pap smear
Yes 219 (74.7 %)
No 51 (17.4 %)
Don’t know 22 (7.5 %)
How important for women in Fiji to have pap smear
(among those who have heard of pap smear)
Very important 211/219 (96.4 %)
Somewhat important 6/219 (2.7 %)
Don’t know 2/219 (0.9 %)
Vaccine information and decision-making
Satisfied with access to information for
decision-making
Yes 196 (66.9 %)
No 38 (13.0 %)
Don’t know 54 (18.4 %)
Discussed decision with family member
Yes 182 (62.1 %)
No 104 (35.5 %)
Don’t know 0
Involved daughter in decision
Yes 213 (72.7 %)
No 62 (21.2 %)
Don’t know 14 (4.8 %)
Obtained advice from health provider or other
community member
Yes 48 (16.4 %)
No 202 (68.9 %)
Don’t know 37 (12.6 %)
Main source of HPV vaccine information
Campaign information pamphlet 219 (74.7 %)
Consent letter 11 (3.8 %)
Newspaper 40 (13.7 %)
Radio 10 (3.4 %)
Magazine article 1 (0.3 %)
NB Percentages for each variable may not equal 100 due to missing data
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consent. The odds of giving consent was almost 7 times
greater among respondents who perceived that women
in Fiji are at risk of HPV compared to those who did not
(OR 6.81, 95 % CI 2.64, 17.56, p < 0.001), and 6 times
greater among respondents who believed that cervical
cancer is common in Fiji compared to those who did
not think it is common (95 % CI 2.1, 17.2, p = 0.001).
The odds of consent was 30 times greater among par-
ents who involved the vaccine-eligible girl in the deci-
sion (OR 30.66, 95 % CI 11.8, 79.9, p < 0.001). Having
discussed the decision with family members was also sig-
nificantly associated with consent (OR 5.66, 95 % CI 2.5,
12.8, p < 0.001). By contrast, those who obtained add-
itional advice from a health provider or other commu-
nity member were not statistically more likely to consent
(OR 3.6, 95 % CI 0.07, 195.7, p = 0.529).
Household income was significantly associated with
consent, with the odds of consent among those in the
middle-income bracket ($FJ100-$FJ199) 5 times greater
than the odds of consent in the lowest income category
(<$FJ100) (OR 5.36, 95 % CI 1.9, 15.4, p = 0.002). By
contrast, parent’s age (p = 0.736) and education level
(p = 0.085) were not significantly related to consent.
A multivariate model exploring factors associated with
consent was constructed including the following ex-
planatory variables: household income, education of re-
spondent, believing that women in Fiji are at risk of
HPV, satisfaction with access to information for
decision-making, discussing the decision with a family
member and involving the daughter in the decision. Be-
lieving that cervical cancer is common in Fiji was not in-
cluded as this is considered to measure a closely related
construct to believing that women in Fiji are at risk of
HPV. The outcome of the model was not different ac-
cording to which of these two risk perception variables
were included, thus we included the variable with the
strongest association in univariate analysis. Satisfaction
with access to information for decision-making
remained highly predictive of consent in the multivariate
model (OR 272.10, 95 % CI 12.7, 5822.6, p < 0.001). No
other variables were significantly associated with consent
in the multivariate model (Table 3).
Attitude towards future HPV vaccination
The large majority of consenting parents said they would
again consent to HPV vaccination for other eligible fam-
ily members if the vaccine were offered in the future
(199/228, 87 %). Some were unsure if they would con-
sent again (26/228, 11 %) and only 1 % said they would
not consent in the future (3/228, 1 %). Among non-
consenting parents, over a third were unsure whether
they would consent if the vaccine became available again
(17/44, 38.6 %), and several reported they would consent
in the future (5/44, 11.3 %).
Parents’ attitudes were fairly consistent regarding the
age they considered appropriate for girls to receive the
HPV vaccine, with most respondents suggesting between
9 and 11 years of age (188/293, 64.2 %). Most respon-
dents said they would also consent to a son receiving
the HPV vaccine if it were offered to boys in the future
(203/293, 69.3 %).
Reasons for vaccine refusal
Forty-four participants (44/293, 15.0 %) reported that
they had not consented to their daughter receiving the
HPV vaccine, and a further 19 were unsure whether
consent had been given (19/293, 6.4 %). Among non-
consenting parents, approximately half (23/44, 52.3 %)
cited concerns about HPV vaccine safety to be the pri-
mary reason for withholding consent (Fig. 2). Many of
these parents commented that the vaccine was new in
Fiji, that they had heard negative information about the
vaccine from friends and in the media, and were fright-
ened for their daughter to receive it. None of the parents
who refused HPV vaccination reported withholding
other vaccinations.
Discussion
Experience with HPV vaccine implementation in LMICs
has been variable [25–29]. In Fiji there was broad ac-
ceptance and uptake of HPV vaccine, with almost 80 %
of survey respondents having consented to vaccination,
and over half reporting their daughter had received all
three doses (58 %). This is consistent with the coverage
recorded by the vaccine campaign, of 62 %, 56 %, and
55 % for doses 1, 2, and 3 respectively [24]. The high
level of vaccine acceptance and uptake in Fiji was an
Fig. 1 Vaccine consent and uptake
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impressive achievement in the context of very limited
baseline public awareness, as demonstrated by the low
reported knowledge of HPV and cervical cancer and fur-
ther supported by the absence of an existing public
health campaign around cervical cancer; limited time for
community education; and a vigorous media debate.
The low reported knowledge of HPV and cervical can-
cer among participants prior to the vaccine campaign in
Table 2 Factors associated with consent: univariate analysis (Generalised estimating equations)
Factors associated with consent: univariate analysis
Consented n (%) Did not consent n (%) OR p value
Demographics
Age (med,IQR) 40 (37,42) 40 (36,46) 0.99 (0.94,10.5) 0.736
Education
Primary only 27 (71.1) 11 (28.9) 2.59 (0.88, 7.66) 0.085
Secondary or higher 193 (87.3) 28 (12.7)
Household income
<100$FJ 60 (72.3) 23 (27.7)
100-199 $FJ 113 (91.9) 10 (8.1) 5.36 (1.87, 15.36) 0.002
200+ $FJ 57 (83.8) 11 (16.2) 2.30 (0.80, 6.58)
Region
Central/Eastern 141 (83.9) 27 (16.1)
Western 70 (87.5) 10 (12.5) 1.61 (0.35, 7.47) 0.510
Northern 19 (73.1) 7 (16.1) 0.51 (0.06, 4.49)
Awareness and knowledge
Heard of HPV prior
Yes 26 (11.9) 3 (8.6) 1.56 (0.40, 6.10) 0.519
No 193 (88.1) 32 (91.4)
Heard of CC prior
Yes 52 (23.0) 9 (21.4) 0.85 (0.25, 2.88) 0.800
No 174 (77.0) 33 (78.6)
CC common in Fiji
Yes 171 (90.0) 16 (61.5) 5.99 (2.08, 17.24) 0.001
No 19 (10.0) 10 (38.5)
Women in Fiji at risk of HPV
Yes 170 (82.1) 15 (40.5) 6.81 (2.64, 17.56) <0.001
No 37 (17.9) 22 (59.5)
Information and decision-making
Satisfied with access to information
Yes 192 (91.4) 1 (5.6) 180.38 (18.26, 1781.92) <0.001
No 18 (8.6) 17 (94.4)
Discussed decision with family member
Yes 165 (73.7) 15 (34.1) 5.66 (2.50, 12.83) <0.001
No 59 (26.3) 29 (65.9)
Involved daughter in decision
Yes 203 (89.8) 9 (23.1) 30.66 (11.77, 79.90) <0.001
No 23 (10.2) 30 (76.9)
Obtained advice from health provider or other community member
Yes 45 (20.6) 2 (8.0) 3.60 (0.07, 195.69) 0.529
No 173 (79.4) 23 (92.0)
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Fiji is consistent with findings from other low and
middle-income settings [7]. This, together with the very
strong association identified between parents’ satisfac-
tion with their access to information and vaccine con-
sent, highlights the critical role of community education
and awareness-raising in HPV vaccine introduction.
Among the variables measured in Fiji, the single most
important factor explaining vaccine consent was satisfac-
tion with access to information for decision-making. Al-
most universally, and irrespective of household income
and other socio-demographic factors, parents who re-
ported having access to sufficient information gave con-
sent for vaccination. Among parents who did not
consent, almost all were not satisfied with their access to
information to guide decision-making.
The overwhelming association identified between par-
ents’ satisfaction with their access to information and
vaccine uptake is positive for future HPV vaccination in
Fiji as it suggests that, with sufficient credible and accur-
ate information, parents are generally willing to accept
HPV vaccination for their daughters. Findings from
other LMICs have also highlighted the important role of
access to information and vaccine uptake. Masika and
colleagues recently reported from Kenya that insufficient
information about the vaccine was one of the main bar-
riers to teachers recommending the vaccine to parents,
and that those with greater knowledge were more likely
to recommend the vaccine [30]. Another recent report
from Kenya describing participation in hospital-based
HPV vaccine delivery reported a limited association be-
tween demographic factors and vaccine uptake, but a
strong relationship between vaccine uptake and being
well-informed about the vaccine program and cervical
cancer [31]. A study in Peru also identified access to suf-
ficient, trusted and credible information as critical to
parental acceptance of the vaccine [32].
Recent years have seen an increasing focus on under-
standing not only the role of information in parental
decision-making for HPV vaccination, but also the type
and source of information most likely to support vaccine
acceptance. Reporting on the experience from HPV vac-
cine introduction in Uganda and Vietnam, Galagan and
colleagues found the people with whom parents dis-
cussed the decision to be a key factor in vaccine uptake
[33]. In those settings, discussion with “community
influencers” (eg teachers, health workers and other com-
munity members) regarding the decision was signifi-
cantly associated with vaccine uptake, playing a more
important role than exposure to materials such as
Table 3 Factors associated with consent: multivariate analysis
(Generalised estimating equation)
Factors associated with consent: multivariate analysis
OR (95 % CI) p value
Household income
100-199 $FJ 6.92 (0.98, 48.5) 0.052
200+ $FJ 0.47 (0.04, 5.82) 0.554
Education 4.33 (0.68, 27.64) 0.122
Women in Fiji at risk of cervical cancer 3.31 (0.39, 27.7) 0.270
Satisfied with access to information 272.10 (12.72, 5822.56) <0.001
Discussed decision with family member 0.94 (0.21,4.23) 0.935
Involved daughter in decision 1.8 (0.47, 7.07) 0.384
Fig. 2 Reasons given for withholding consent for HPV vaccination
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information leaflets, banners and radio announcements.
In Fiji we found that, despite local health providers being
cited as a trusted source of health information, few par-
ents reported having obtained information about the
campaign from health providers or other community
members, and those who did were no more or less likely
to consent. The short time period available in Fiji for
community education and discussion ahead of vaccine
roll-out may have limited parents’ access to sufficient in-
formation and their ability to actively seek out further
information in the community.
Despite the absence in our study of an identified role
for health worker or other community member consult-
ation in parent decision-making in Fiji, in univariate
analysis both discussion with family members and in-
volvement of the vaccine-eligible girl in decision-making
were strongly associated with consent. There is limited
information from LMIC regarding the extent to which
vaccine-eligible girls themselves are involved in HPV
vaccine decision-making and the influence they may
have on parental consent or refusal. A qualitative study
of vaccine introduction in Peru revealed that the
vaccine-eligible girls had an active role in decision-
making, particularly in urban areas, citing cases of par-
ents being convinced by daughters to either consent or
refuse. This is consistent with findings from high-
income countries that parent-daughter interaction re-
garding HPV vaccination decision-making plays an
important role in vaccine uptake [34–36]. Given the po-
tential then for vaccine-eligible girls themselves to be ac-
tively involved in decision-making, and also to foster
awareness about HPV among future generations, com-
munity education and sensitisation should incorporate a
strong focus on increasing understanding and accept-
ance among these young adolescents. This should also
include adolescent boys, as potential future vaccine re-
cipients, noting that a substantial proportion of respon-
dents in Fiji indicated they would consent to HPV
vaccination for their sons if it were offered.
In many settings limited knowledge about HPV and
cervical cancer has been described among the health
workforce [37–43]. Future HPV implementation in Fiji
should include training and information targeting health
professionals, as those identified by respondents to be a
trusted source of health information, to ensure they are
able to respond effectively to community queries and
concerns. Galagan and colleagues also found in Uganda
and Vietnam that teachers were important community
influencers for parent decision-making [33]. We did not
specifically enquire regarding the role of teachers in sup-
porting vaccine decision making for parents; however as
HPV vaccine has been primarily delivered in Fiji through
the school-based immunisation program this is an im-
portant consideration for future delivery to ensure that
teachers are able to respond effectively and accurately to
parents’ concerns.
Respondents who did not consent to vaccination
mainly attributed their refusal to safety concerns. This is
consistent with reports from other settings describing
vaccine acceptability and concerns post-introduction.
For example, a study of vaccine acceptance and
decision-making among parents of vaccine-eligible girls
in Vietnam described similar safety concerns and suspi-
cion that the vaccine was experimental [44]. A report
from Romania attributed the very low HPV vaccine
coverage achieved in their campaign (2.5 %) to commu-
nity concerns about vaccine safety, which had been
fuelled by rumours and negative media [26].
Despite the short time to sensitise the community, the
HPV vaccine campaign in Fiji was largely successful in
providing the information needed by parents to make a
decision about HPV vaccination for their daughter. Fu-
ture HPV vaccine implementation in Fiji will require a
continued strong focus on information and education,
particularly to ensure there is enough reliable infor-
mation from trusted sources in the community to
counter any negative media and rumours. Strategies
to strengthen the cervical screening program should
also be a priority, as participation rates in Fiji are
very low, and it is important that vaccine introduction
not be considered to replace the need for regular cer-
vical screening [21].
A limitation of this study is the collection of data by
telephone interview. This approach was taken in order
to maximise participation from geographically diverse
areas in the context of limited time and resources
available for data collection. This approach naturally re-
stricts participation to those individuals who have access
to a functioning telephone, raising concerns of over-
representation by higher socio-economic groups. How-
ever, in support of this approach, mobile telephone own-
ership and use in low and middle income settings has
increased dramatically in recent years [45]. Data indicate
that mobile phone ownership in Fiji is common, with 81
mobile phone subscriptions per 100 people in 2010 and
65 % of the population being covered by a cellular net-
work [45]. Furthermore, while not an ideal measure of
socio-economic status, the household income reported
by participants is in line with population averages [46],
and HPV vaccine-uptake in the survey sample is consist-
ent with the broader population [24]. Notwithstanding,
the use of telephone interviewing is likely to have re-
duced participation in the study, with a large number of
parents of girls in participating classes not being con-
tacted by the survey team to invite participation due to
missing or incorrect phone number. As such we cannot
rule out a potential bias in our study population and this
should be considered in interpretation of findings.
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A further potential limitation is the measurement of
parents’ satisfaction with access to information using a
simple binary satisfied/not satisfied response. Given the
important relationship that has been identified between
satisfaction with access to information and vaccine con-
sent, collection of more detailed information in relation
to satisfaction would have enabled more precise meas-
urement and greater insight into the relationship be-
tween this variable and vaccine uptake.
Finally, we focused our enquiry around vaccine con-
sent, which may not always be a true indicator of vac-
cine acceptance. The large majority of parents reported
no subsequent concern about their decision to permit
vaccination, and a relatively small number of girls had
been consented but not received all three doses. Not-
withstanding, we may have missed the opportunity to
document attitudes and concerns among parents who
provided consent but ultimately did not permit vaccin-
ation. For example, absenteeism on scheduled vaccine
days may reflect a deliberate desire among some parents
to avoid vaccination for their daughter despite having
previously given consent. Future activities exploring par-
ental acceptance of vaccination should enquire not only
around vaccine consent, but also actual receipt of vac-
cination among children of consenting parents.
Conclusion
Despite the challenges of low baseline community
awareness of HPV, a short lead-time and significant
negative media reporting, Fiji successfully implemented
an HPV vaccine campaign that was largely acceptable to
parents. With a very strong relationship identified be-
tween vaccine consent and satisfaction with access to in-
formation for vaccine decision-making, the findings of
this survey highlight the critical role of effective commu-
nity education and ensuring that families have ready ac-
cess to a trusted source of accurate information to
address any questions or concerns about the vaccine.
This is one of the first experiences with HPV vaccine
introduction in a resource-limited Pacific island nation.
Guided by this experience, the Government of Fiji took
the decision to include HPV vaccination in their national
immunisation program in 2013. These findings have
helped refine community education approaches to fur-
ther strengthen community acceptance and support
HPV vaccine uptake by the target population.
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